Illumina, Inc ILMN Stock Price, News, Quote & History

According to analysts’ consensus price target of $256.00, Illumina has a forecasted upside of 22.8% from its current price of $208.52. FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns DotBig are calculated on a monthly basis by Value Line and posted mid-month. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Powered and implemented by FactSet Digital Solutions Group.

Illumina saw a decline in short interest during the month of November. As of November 15th, there was short interest totaling 4,370,000 shares, a decline of 9.3% from the October 31st total of 4,820,000 shares. Based on an average daily trading volume, of 1,620,000 shares, the short-interest ratio is presently 2.7 days.

• The company was incorporated in 1998 and is based in San Diego, California.
• Benzinga tracks 150 analyst firms and reports on their stock expectations.
• Illumina’s stock is owned by a variety of institutional and retail investors.
• Historical and current end-of-day data provided by FACTSET.
• Shares are now below their 50-day moving average, according to MarketSmith.com.
• Our Illumina Revenue and Thermo Fisher Scientific Revenue dashboards provide more insight into the companies’ sales.

The price that Illumina is paying for GRAIL won’t matter over the long run — if GRAIL is successful in developing and marketing liquid biopsy products. GRAIL hopes to launch its first product, multicancer early detection test Galleri, next year for laboratory use only. With Illumina’s shares trading at more than 42 times expected earnings, the company will need to deliver some good news dotbig.com/markets/stocks/ILMN/ soon to convince investors the healthcare stock is worth buying at its premium valuation. 13 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Illumina in the last twelve months. There are currently 1 sell rating, 5 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" ILMN shares.

Health

It is mission critical for us to deliver innovative, flexible, and scalable solutions to meet the needs of our customers. As a global company that places high value on collaborative interactions, rapid delivery of solutions, and providing the highest level of quality, we strive to meet this challenge. Illumina innovative sequencing and array technologies are fueling groundbreaking advancements in life science stock price of Illumina research, translational and consumer genomics, and molecular diagnostics. We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management.

Real Money’s message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site’s moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Raders could probe the DotBig long side of ILMN on a pullback or correction to the $220 area. Risk to $202." It looks like our recommendation could be stopped out with a loss very soon, so let’s check out the charts and indicators of the provider of genetic analysis products again. Grail sells Galleri, a test that analyzes a single blood draw for more than 50 types of cancer.

Illumina Has Become a Powerhouse of the Chinese Genomics Industry

Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company’s revenue streams are.

Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, and premium investing services. Thermo Fisher Scientific manufactures analytical laboratory instruments used in various tests, and the pandemic has increased demand for these instruments. Its sales growth is buoyed by continued market share gains for its instruments. Illumina has a recurring revenue model from consumables and accessories, accounting for 83% of the company’s total sales in 2021. 2.78% of the outstanding shares of Illumina have been sold short. The company’s average rating score is 2.46, and is based on 7 buy ratings, 5 hold ratings, and 1 sell rating. The stock of the provider of genetic analysis products is pulling back more than expected, so here’s what may be next.

About Illumina (NASDAQ:ILMN) Stock

We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters. Market capitalization is calculated by taking a company’s share price and multiplying it by the total number of shares. In the Morningstar Illumina stock Style Box, large-cap names account for the largest 70% of U.S. stocks, mid-cap names account for the largest 70–90%, and small-cap names are the remaining 10% of companies. Illumina’s sales have been rising due to the booming demand for gene sequencing.

Should You Buy Illumina (ILMN) Ahead of Earnings?

The company has an average price target of $246.71 with a high of $300.00 and a low of $175.00. Dividend yield allows investors, particularly those interested in dividend-paying stocks, to compare the https://dotbig.com/ relationship between a stock’s price and how it rewards stockholders through dividends. The formula for calculating dividend yield is to divide the annual dividend paid per share by the stock price.

Where to Invest Your Money in Q4 2022

The U.S. is working hard to build more advanced nuclear plants to achieve clean energy and climate goals. However, America’s reliance on Russia for uranium has grave implications for national security. Incentives are now up for grabs to help revive the domestic uranium industry. Sign-up to receive the latest news and ratings for Illumina and its competitors with MarketBeat’s FREE daily newsletter.

Illumina does not have a long track record of dividend growth. Short interest in Illumina has recently decreased by 9.34%, indicating that investor sentiment is improving significantly. You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Analysts have been eager to weigh in on the Healthcare stock price of Illumina sector with new ratings on Avadel Pharmaceuticals (AVDL – Research Report), Illumina (ILMN – Research Report) and Regeneron (REGN – Research Report). Analysts have been eager to weigh in on the Healthcare sector with new ratings on Illumina (ILMN – Research Report), Cardinal Health (CAH – Research Report) and Beam Therapeutics (BEAM – Research Report).